A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 99 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Spondylarthritis with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · United States.
Among the 27 studies in Spondylarthritis with a site in United States, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 14th registered.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
Browse Spondylarthritis studies →6 of the 27 studies in Spondylarthritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 2–99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 316 is above the median of 108 across 106 interventional studies indexed under Spondylarthritis.
Median enrollment 329 across the 14 interventional studies, 134 across the 13 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Spondylarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Spondylarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
Drug: Ixekizumab
Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
Drug: Ixekizumab
Double Blind Period: Placebo given SC Q2W to week 14. Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.
Drug: Ixekizumab · Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Percentage of Participants Achieving an ASAS20 Response
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, geographic region, baseline CRP status, number of prior tumor necrosis factor inhibitor (TNFi), baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants Achieving ASDAS Inactive Disease
ASDAS is a composite index to assess disease activity in AS. ASDAS Inactive Disease is defined as a score of \<1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 16
Percentage of Participants Achieving ASDAS <2.1
ASDAS is a composite index to assess disease activity in AS. ASDAS \<2.1 defines moderate disease activity. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 16
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in ASAS Health Index (ASAS HI)
The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the patient needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)
The study used MRI with fat-saturating techniques such as short tau inversion recovery (STIR) to look for the presence of bone marrow edema. The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of the 23 disco-vertebral units (DVU) of the spine (from C2 to S1), capturing bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.LS mean was determined by analysis of covariance (ANCOVA) with treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value.
Time frame: Baseline, Week 16
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Chest Expansion
Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While patients have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Occiput to Wall Distance
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 16
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 16
Percentage of Participants With Anterior Uveitis
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Week 16
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, baseline CRP status, number of prior TNFi and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, higher the score greated the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).
Time frame: Baseline, Week 52
Percentage of Participants With Anti-Ixekizumab Antibodies
A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Week 16
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.
Time frame: Week 16
Blinded Treatment Dosing Period (Week 0 to Week 16), Extended Treatment Period (Week 16 to Week 52) followed by post-treatment follow-up period occurring from last treatment visit (week 52), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.
| Milestone | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W |
|---|---|---|---|
| Started | 104 | 114 | 98 |
| Completed | 93 | 99 | 90 |
| Not completed | 11 | 15 | 8 |
| Withdrew: Adverse event | 2 | 9 | 2 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 3 | 4 |
| Milestone | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W |
|---|---|---|---|
| Started | 93 | 98 | 90 |
| Completed | 81 | 89 | 80 |
| Not completed | 12 | 9 | 10 |
| Withdrew: Adverse event | 1 | 4 | 5 |
| Withdrew: Lack of efficacy | 7 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 3 |
| Milestone | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W |
|---|---|---|---|
| Started | 5 | 34 | 22 |
| Completed | 0 | 8 | 3 |
| Not completed | 5 | 26 | 19 |
| Withdrew: Adverse event | 2 | 12 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 12 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: No progressive improvement | 0 | 1 | 0 |
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response | 12.5 | 25.4 | 30.6 |
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants Achieving an ASAS20 Response | 29.8 | 48.2 | 46.9 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, geographic region, baseline CRP status, number of prior tumor necrosis factor inhibitor (TNFi), baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.11 ± 0.099 | -1.16 ± 0.094 | -1.13 ± 0.103 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response | 9.6 | 21.9 | 23.5 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -0.92 ± 0.212 | -2.17 ± 0.202 | -2.09 ± 0.221 |
The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | -0.64 ± 0.215 | -1.69 ± 0.205 | -1.92 ± 0.225 |
ASDAS is a composite index to assess disease activity in AS. ASDAS Inactive Disease is defined as a score of \<1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants Achieving ASDAS Inactive Disease | 1.0 | 3.5 | 5.1 |
ASDAS is a composite index to assess disease activity in AS. ASDAS \<2.1 defines moderate disease activity. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants Achieving ASDAS <2.1 | 4.8 | 17.5 | 16.3 |
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSmean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| SF-36 MCS | 2.7410 ± 0.9452 | 3.5099 ± 0.9074 | 3.6514 ± 0.9921 |
| SF-36 PCS | 1.3638 ± 0.8146 | 6.5785 ± 0.7763 | 6.1223 ± 0.8465 |
The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the patient needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in ASAS Health Index (ASAS HI) | -0.89 ± 0.338 | -1.92 ± 0.322 | -1.58 ± 0.352 |
The study used MRI with fat-saturating techniques such as short tau inversion recovery (STIR) to look for the presence of bone marrow edema. The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of the 23 disco-vertebral units (DVU) of the spine (from C2 to S1), capturing bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease.LS mean was determined by analysis of covariance (ANCOVA) with treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score) | 1.03 ± 0.379 | -0.92 ± 0.373 | -1.14 ± 0.414 |
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, geographic region, baseline CRP status, number of prior TNF inhibitors used and baseline value.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) | 3.29 ± 1.402 | -2.99 ± 1.384 | -3.97 ± 1.534 |
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, visit, and treatment-by-visit interaction as fixed factors.
| milligram per liter (mg/L) | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP) | 9.719 ± 2.7383 | -11.096 ± 2.6190 | -8.121 ± 2.8829 |
BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) | -0.046 ± 0.0939 | -0.349 ± 0.0897 | -0.217 ± 0.0981 |
Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While patients have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
| centimeter(cm) | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Chest Expansion | 0.04 ± 0.644 | 1.27 ± 0.618 | 0.27 ± 0.655 |
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by MMRM with factors for treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
| cm | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Occiput to Wall Distance | 0.35 ± 0.384 | 0.03 ± 0.365 | -0.65 ± 0.399 |
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) | -1.9 ± 0.43 | -1.8 ± 0.40 | -2.2 ± 0.42 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score | -1.9 ± 0.44 | -2.3 ± 0.40 | -1.8 ± 0.45 |
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.
| Tender Joint Count | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Scores | -3.9 ± 0.79 | -4.8 ± 0.69 | -5.0 ± 0.79 |
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction.
| Swollen Joint Count | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Scores | -2.4 ± 0.51 | -2.6 ± 0.49 | -3.0 ± 0.54 |
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants With Anterior Uveitis | 0 | 1.8 | 3.1 |
The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score | -0.7 ± 0.24 | -2.0 ± 0.23 | -1.7 ± 0.25 |
The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by MMRM with treatment, geographic region, baseline CRP status, number of prior TNFi, baseline value, visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ) | -1.8 ± 0.50 | -3.0 ± 0.48 | -2.4 ± 0.52 |
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, baseline CRP status, number of prior TNFi and baseline value as fixed factors.
| Units on a scale | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Overall Work Impairment Score | -9.84 ± 3.733 | -20.97 ± 4.016 | -23.50 ± 4.225 |
| Percentage of Activity Impairment | -10.1 ± 2.60 | -16.5 ± 2.44 | -18.4 ± 2.74 |
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, higher the score greated the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).
| Units on a scale | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W |
|---|---|---|---|
| Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score | -9.84 ± 34.435 | -5.52 ± 19.553 | -2.33 ± 24.019 |
A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| Percentage of Participants | Placebo | 80 mg Q4W Ixekizumab | 80 mg Q2W Ixekizumab |
|---|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 2.9 | 7.1 | 4.1 |
Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.
| Microgram per milliliters (µg/mL) | 80 mg Q4W Ixekizumab (Starting Dose 80 mg) | 80 mg Q4W Ixekizumab (Starting Dose 160 mg) | 80 mg Q2W Ixekizumab (Starting Dose 80 mg) | 80 mg Q2W Ixekizumab (Starting Dose 160 mg) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss) | 2.10 ± 106 | 2.47 ± 101 | 6.27 ± 158 | 8.52 ± 50 |
Collected over Up To 76 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg Q2W Ixekizumab-Blinded Treatment Period | 1/98 (1%) | 3/98 (3.1%) | 25/98 (25.5%) |
| 80 mg Q4W Ixekizumab-Blinded Treatment Period | 0/114 (0%) | 4/114 (3.5%) | 25/114 (21.9%) |
| PBO-Blinded Treatment Period | 0/104 (0%) | 5/104 (4.8%) | 12/104 (11.5%) |
| IXE80Q2W/IXE80Q2W-Extended Treatment Period | 0/90 (0%) | 1/90 (1.1%) | 26/90 (28.9%) |
| IXE80Q4W/IXE80Q4W-Extended Treatment Period | 0/98 (0%) | 2/98 (2%) | 19/98 (19.4%) |
| PBO/IXE-Extended Treatment Period | 0/93 (0%) | 6/93 (6.5%) | 19/93 (20.4%) |
| IXE80Q2W-Follow-up Period | 0/22 (0%) | 1/22 (4.5%) | 1/22 (4.5%) |
| IXE80Q4W-Follow-up Period | 0/34 (0%) | 2/34 (5.9%) | 3/34 (8.8%) |
| PBO-Follow-up Period | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | 80 mg Q2W Ixekizumab-Blinded Treatment Period | 80 mg Q4W Ixekizumab-Blinded Treatment Period | PBO-Blinded Treatment Period | IXE80Q2W/IXE80Q2W-Extended Treatment Period | IXE80Q4W/IXE80Q4W-Extended Treatment Period | PBO/IXE-Extended Treatment Period | IXE80Q2W-Follow-up Period | IXE80Q4W-Follow-up Period | PBO-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 0/93 | 1/22 | 0/34 | 0/5 |
| Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 0/93 | 0/22 | 1/34 | 0/5 |
| Loss of consciousnessNervous system disorders | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 0/93 | 0/22 | 1/34 | 0/5 |
| SyncopeNervous system disorders | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 0/93 | 0/22 | 1/34 | 0/5 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 0/93 | 0/22 | 1/34 | 0/5 |
| GastroenteritisInfections and infestations | 0/98 | 0/114 | 0/104 | 1/90 | 0/98 | 0/93 | 0/22 | 0/34 | 0/5 |
| Acute myocardial infarctionCardiac disorders | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 1/93 | 0/22 | 0/34 | 0/5 |
| BradycardiaCardiac disorders | 0/98 | 0/114 | 0/104 | 0/90 | 1/98 | 1/93 | 0/22 | 0/34 | 0/5 |
| Inguinal herniaGastrointestinal disorders | 0/98 | 0/114 | 1/104 | 0/90 | 0/98 | 1/93 | 0/22 | 0/34 | 0/5 |
| PneumoniaInfections and infestations | 0/98 | 0/114 | 0/104 | 0/90 | 0/98 | 1/93 | 0/22 | 0/34 | 0/5 |
| Event | 80 mg Q2W Ixekizumab-Blinded Treatment Period | 80 mg Q4W Ixekizumab-Blinded Treatment Period | PBO-Blinded Treatment Period | IXE80Q2W/IXE80Q2W-Extended Treatment Period | IXE80Q4W/IXE80Q4W-Extended Treatment Period | PBO/IXE-Extended Treatment Period | IXE80Q2W-Follow-up Period | IXE80Q4W-Follow-up Period | PBO-Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|
| Blood triglycerides increasedInvestigations | 0/98 | 0/114 | 1/104 | 1/90 | 0/98 | 1/93 | 0/22 | 0/34 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 4/98 | 9/114 | 3/104 | 8/90 | 4/98 | 5/93 | 0/22 | 0/34 | 0/5 |
| Injection site reactionGeneral disorders | 8/98 | 3/114 | 1/104 | 5/90 | 2/98 | 3/93 | 0/22 | 0/34 | 0/5 |
| Vulvovaginal candidiasisInfections and infestations | 0/23 | 0/23 | 0/17 | 0/22 | 0/17 | 1/16 | 0/4 | 0/9 | 0/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/98 | 7/114 | 4/104 | 2/90 | 4/98 | 4/93 | 1/22 | 1/34 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 3/98 | 1/114 | 2/104 | 5/90 | 6/98 | 0/93 | 0/22 | 0/34 | 0/5 |
| NasopharyngitisInfections and infestations | 4/98 | 5/114 | 2/104 | 4/90 | 3/98 | 3/93 | 0/22 | 2/34 | 0/5 |
| Vulvovaginal burning sensationReproductive system and breast disorders | 0/23 | 0/23 | 0/17 | 0/22 | 1/17 | 0/16 | 0/4 | 0/9 | 0/1 |
| Vulvovaginal drynessReproductive system and breast disorders | 0/23 | 0/23 | 0/17 | 0/22 | 1/17 | 0/16 | 0/4 | 0/9 | 0/1 |
| Urinary tract infectionInfections and infestations | 2/98 | 0/114 | 0/104 | 5/90 | 2/98 | 2/93 | 0/22 | 0/34 | 0/5 |
All randomized participants
| Age, Continuous(Years) | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W | Total |
|---|---|---|---|---|
| Mean | 46.6 ± 12.72 | 47.4 ± 13.36 | 44.2 ± 10.79 | 46.1 ± 12.43 |
| Sex: Female, Male(Participants) | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W | Total |
|---|---|---|---|---|
| Female | 17 | 23 | 23 | 63 |
| Male | 87 | 91 | 75 | 253 |
| Ethnicity (NIH/OMB)(Participants) | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 33 | 32 | 35 | 100 |
| Not Hispanic or Latino | 63 | 70 | 53 | 186 |
| Unknown or Not Reported | 8 | 12 | 10 | 30 |
| Race (NIH/OMB)(Participants) | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 4 | 12 |
| Asian | 13 | 14 | 13 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 2 | 5 |
| White | 85 | 91 | 78 | 254 |
| More than one race | 1 | 2 | 1 | 4 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | PBO/IXE | IXE80Q4W/IXE80Q4W | IXE80Q2W/IXE80Q2W | Total |
|---|---|---|---|---|
| Puerto Rico | 1 | 2 | 4 | 7 |
| Argentina | 6 | 7 | 5 | 18 |
| United States | 14 | 14 | 12 | 40 |
| United Kingdom | 9 | 6 | 5 | 20 |
| Spain | 3 | 7 | 4 | 14 |
| Canada | 1 | 5 | 0 | 6 |
| South Korea | 12 | 11 | 11 | 34 |
| Netherlands | 1 | 2 | 0 | 3 |
| Finland | 0 | 3 | 2 | 5 |
| Brazil | 10 | 8 | 10 | 28 |
| Poland | 22 | 24 | 20 | 66 |
| Italy | 0 | 1 | 1 | 2 |
| Mexico | 13 | 13 | 13 | 39 |
| Israel | 5 | 5 | 6 | 16 |
| France | 7 | 5 | 5 | 17 |
| Germany | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2016 to primary completion in May 2018, 25 months.
Results were first posted in Oct 2019, 1 year 5 months after primary completion. A results delay was requested in Jun 2018.
Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 25 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab